Biologics Industry Report: One of the fastest-growing sectors in the pharmaceutical industry, with a market size expected to reach 675.2 billion yuan.

Content Summary: Biologics have become one of the fastest-growing segments in the pharmaceutical industry. As the population ages and public awareness of health continues to rise, China’s innovative drug market has demonstrated strong momentum in both size and growth potential. In 2024, the Chinese biologics market grew from 312 billion yuan in 2019 to 587.1 billion yuan. By 2025, the Chinese biologics market is projected to reach 675.2 billion yuan, with an estimated potential of 1.1491 trillion yuan over the next five years. Original research biologics that are first developed and launched onto the market are also referred to as innovative biologics. Biologics represent the pinnacle of modern medicine and biotechnology, serving as a prime example of precision medicine. As one of the world’s most active countries in biotechnology research, China has played a pivotal role in the development of the biologics market. Innovation remains the core driving force; the biologics industry is capital-intensive and requires substantial investment in R&D. Thanks to favorable national policies, steadily increasing R&D spending, and remarkable advances in biotechnology, China’s market for original research biologics has been growing rapidly. By 2030, China’s R&D expenditure on biologics is expected to climb to 308.8 billion yuan, and the market size for original research biologics could surpass 1 trillion yuan.

Listed company: Shutai Shen [300204], Hengrui Medicine [600276], WuXi Biologics [02269], BeiGene [06160], Sinovac Biotech [SVA], WuXi AppTec [603259], Zhifei Biological [300122], Wantai Biological [603392], Changchun High-Tech [000661], Kailiang [002821], Watson Bio [300142], Chengdu Institute of Biological Products [688739], Aim Vaccine [06660], LideMan [300289], Daan Gene [002030], Dian Diagnostics [300244], Kehua Bio [002022], Tiantan Biological [600161], Shanghai Laishi [002252], Wuhan Institute of Biological Products [002007], Sansheng National Health [688336], Fosun Pharma [600196]

Relevant enterprises: China Biopharmaceutical Corporation, Baitai Biopharmaceutical Co., Ltd., Nanjing Xuanke Biotechnology Co., Ltd., Beijing Sannuo Jiayi Biotechnology Co., Ltd.

Keywords: biopharmaceutical industry policies, biopharmaceutical industry value chain, biopharmaceutical market size, R&D expenditure in the biopharmaceutical industry, competitive landscape of the biopharmaceutical industry, trends in the development of the biopharmaceutical industry

I. Definition and Classification of the Biologics Industry

Biological agents are pharmaceutical products manufactured using biological methods and sources, designed to replicate the activity of naturally occurring substances. For example, the inactivated COVID-19 vaccine is a typical biological agent. Insulin, human growth hormone, as well as antibody-based drugs and cytokine-based drugs used to treat tumors, all fall under the category of biological agents. Based on their characteristics and intended uses, biological agents can be classified into vaccine preparations, blood products, biopharmaceuticals, diagnostic reagents, and other types of biological agents. Further classification by source or mechanism of action includes recombinant protein drugs, antibody drugs, and nucleic acid drugs.

Biologic drugs are a relatively new class of medications that have gained prominence due to their high safety profile, precision, efficacy, and short development cycles. As a result, the term “biologic drugs” is becoming increasingly familiar to the public. The specific characteristics of biologic drugs are as follows:

II. Current Status of the Biologics Industry Development

1. Current Status of the Global Biologics Industry

Biological agents, primarily used for disease treatment, are characterized by their high specificity, remarkable efficacy, and relatively mild side effects, making them one of the fastest-growing sectors in the pharmaceutical industry. The first-ever biologic agents developed and launched on the market—known as originator biologics—are also referred to as innovative biologics. As the global population ages and public awareness of health continues to rise, both the size and growth potential of the global innovative drug market are demonstrating strong momentum. Biological agents represent the pinnacle of achievements in modern medicine and biotechnology, serving as a prime example of precision medicine. Consequently, countries around the world are accelerating innovation and research & development in biological agents, driving rapid market growth.

According to statistics, the global biopharmaceutical market size grew from USD 286.4 billion in 2019 to USD 461.6 billion in 2024, while the market size for originator biopharmaceuticals expanded from USD 268.9 billion in 2019 to USD 427.9 billion. It is projected that by 2025, the global biopharmaceutical market will reach USD 521.6 billion, and the global market for originator biopharmaceuticals will amount to USD 482 billion.

2. Current Status of China’s Biopharmaceutical Industry

As one of the world’s most active countries in biotechnology research, China has played a significant role in the development of the biopharmaceutical market. In 2024, China’s biopharmaceutical market size grew from 312 billion yuan in 2019 to 587.1 billion yuan. It is projected that China’s biopharmaceutical market will reach 675.2 billion yuan in 2025 and is expected to hit 1.1491 trillion yuan over the next five years.

Innovation remains the core driving force, regulatory efficiency continues to improve, healthcare insurance reforms are deepening, and capital consolidation is accelerating. As a result, China’s pharmaceutical industry is stepping into a new era of high-quality development and internationalized innovation. The biopharmaceutical sector is capital-intensive and requires substantial investment in R&D. It is projected that China’s R&D expenditure on biopharmaceuticals will grow from 76.2 billion yuan in 2017 to 308.8 billion yuan by 2030.

Note: This excerpt is taken from Zhiyan Consulting The published... 2025 China Biopharmaceutical Industry: Policy Analysis, Industrial Chain, Market Size, R&D Expenditure, Competitive Landscape, and Future Development Trends—The biopharmaceutical sector has become one of the fastest-growing segments in the pharmaceutical industry, with a market size expected to reach 675.2 billion yuan [Chart]. 》Industry analysis articles—For access to the full content of industry articles, please go to Zhiyan Consulting Official Website Search and view.

Zhiyan Consulting The newly released “China Biopharmaceutical Industry Market Competition Status and Industry Demand Assessment Report” is based on authoritative data published by the National Bureau of Statistics, government agencies, and industry associations, combined with comprehensive data collection and analysis—including in-depth research findings, expert feedback, and internal operational data—to enhance the efficiency of our clients’ business decision-making. This report focuses on China... Biological agent We have conducted an in-depth investigation and study of the current industry situation and market conditions, and based on the industry’s development trajectory, we have made a prudent assessment of future prospects and trends. This enables us to help investors identify new market investment opportunities and enter the market. Biological agent Industry investment layouts provide crucial decision-making reference bases.

Zhiyan Consulting With 15 years of focused expertise in industrial consulting, we are a professional service provider in China’s industrial consulting sector. Our brand philosophy is “Driving industrial development through information and empowering enterprises with data-driven investment decisions.” We offer specialized industrial consulting services to businesses, with our key offerings including: High-quality industry research reports, custom-tailored studies, monthly special topics, feasibility studies, business plans, and industrial planning. Wait. Provide Weekly Report / Monthly Report / Quarterly Report / Annual Report Receive regular reports and customized data covering policy monitoring, corporate developments, industry statistics, product price fluctuations, an overview of investment and financing activities, market opportunities, and risk analyses.